The Lead Episode 28: Results of the FRAIL-AF Randomized Controlled Trial-The Lead Episode 28 Speaker Information

The Lead Episode 28 Speaker Information

Pdf Summary

The article being discussed is about the safety of switching from a Vitamin K Antagonist (VKA) to a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) in frail older patients with atrial fibrillation. The study, called FRAIL-AF, was a randomized controlled trial that aimed to evaluate the safety of switching anticoagulation therapy in this population.<br /><br />The authors of the article include Linda P.T. Joosten, MD, Sander van Doorn MD, PhD, and other medical professionals. The article was published in Circulation: AHA Journals.<br /><br />The discussion is hosted by William H. Sauer, MD, FHRS, CCDS, from Brigham and Women's Hospital. Other contributors include Christian Thomas Ruﬀ, MD, MPH, and Erik Andrews, MD, MPH, also from Brigham and Women's Hospital.<br /><br />In terms of disclosures, Erik Andrews and William H. Sauer have received honoraria, speaking fees, and consulting fees from various medical companies. They have also conducted research funded by Medtronic. Christian Thomas Ruﬀ has received honoraria, speaking fees, and consulting fees from pharmaceutical companies and has conducted research funded by Daiichi and MedImmune.<br /><br />Overall, the focus of the discussion is on the safety and implications of switching anticoagulation therapy in frail older patients with atrial fibrillation.

Keywords

Vitamin K Antagonist

Non-Vitamin K Antagonist Oral Anticoagulant

frail older patients

atrial fibrillation

FRAIL-AF

safety

anticoagulation therapy

Circulation: AHA Journals

Brigham and Women's Hospital

implications